OCGN Stock Forecast: Ocugen Inc extends decline as it misses on third quarter earnings
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:OCGN fell by 7.37% during Tuesday’s trading session.
- Ocugen reported its third-quarter financial results on Tuesday.
- Ocugen is targeting COVID-19 vaccinations for children.
NASDAQ:OCGN extended its recent skid and has now lost nearly 50% over the past five trading days. On Tuesday, shares dropped a further 7.37% and closed the trading session at $8.92. It has been a bumpy ride for Ocugen shareholders as of late, and on Tuesday a disappointing earnings report for the third quarter magnified its losses. Ocugen’s report came on a day full of high-profile companies reporting as well. Other companies like PayPal (NASDAQ:PYPL), Palantir (NYSE:PLTR), Coinbase (NASDAQ:COIN), and Nio (NYSE:NIO) all reported on Tuesday, so Ocugen was lost in the shuffle. Still, the stock has been on a steep downward trajectory over the past couple of weeks, despite numerous catalysts that could be interpreted as being positive for the future of the company.
Stay up to speed with hot stocks' news!
As mentioned earlier, Ocugen reported its third-quarter financial results, narrowly missing Wall Street expectations. Ocugen saw a loss of $10.8 million and earnings per share of a loss of $0.05. This was a wider loss than expected by analysts who were forecasting a loss of $0.04 per share for the quarter. The earnings miss only proved to add to Ocugen’s recent struggles, as the stock continued to sell-off.
OCGN stock price
Ocugen did report some potential catalysts as the company heads into 2022, including focussing on children for its COVID-19 vaccine candidate: Covaxin. Ocugen generally operates in North America, where vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have dominated usage. Now that the US and Canada are both looking towards vaccinating children, Ocugen is eyeing this as an opportunity to gain an important market share for its vaccine.
- NASDAQ:OCGN fell by 7.37% during Tuesday’s trading session.
- Ocugen reported its third-quarter financial results on Tuesday.
- Ocugen is targeting COVID-19 vaccinations for children.
NASDAQ:OCGN extended its recent skid and has now lost nearly 50% over the past five trading days. On Tuesday, shares dropped a further 7.37% and closed the trading session at $8.92. It has been a bumpy ride for Ocugen shareholders as of late, and on Tuesday a disappointing earnings report for the third quarter magnified its losses. Ocugen’s report came on a day full of high-profile companies reporting as well. Other companies like PayPal (NASDAQ:PYPL), Palantir (NYSE:PLTR), Coinbase (NASDAQ:COIN), and Nio (NYSE:NIO) all reported on Tuesday, so Ocugen was lost in the shuffle. Still, the stock has been on a steep downward trajectory over the past couple of weeks, despite numerous catalysts that could be interpreted as being positive for the future of the company.
Stay up to speed with hot stocks' news!
As mentioned earlier, Ocugen reported its third-quarter financial results, narrowly missing Wall Street expectations. Ocugen saw a loss of $10.8 million and earnings per share of a loss of $0.05. This was a wider loss than expected by analysts who were forecasting a loss of $0.04 per share for the quarter. The earnings miss only proved to add to Ocugen’s recent struggles, as the stock continued to sell-off.
OCGN stock price
Ocugen did report some potential catalysts as the company heads into 2022, including focussing on children for its COVID-19 vaccine candidate: Covaxin. Ocugen generally operates in North America, where vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have dominated usage. Now that the US and Canada are both looking towards vaccinating children, Ocugen is eyeing this as an opportunity to gain an important market share for its vaccine.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.